Abstract: In certain embodiments a construct for performing gene editing in a mammalian cell is provided. In certain embodiments the construct comprises a targeting moiety that binds a surface marker on a cell (e.g., surface receptor), where the targeting moiety is attached to a complex comprising a class 2 CRISPR/Cas endonuclease complexed with a corresponding CRISPR/Cas guide RNA that hybridizes to a target sequence within the genomic DNA of the cell.

Abstract: The invention provides compounds of Formula XXIII: wherein R1 is hydrogen, alkyl, acyl, or silyl, R2 is hydrogen, alkyl, benzyl, acyl, or ester, and R3 is hydrogen, alkyl, an aromatic group, azacyclic, carbocycle, aryl, cycloalkyl, heterocycloalkyl, heterocycle, heteroaryl, heteroalkyl, acyl, or ester, as well as derivatives and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.

Abstract: Inhibitors of USP30 and methods of using inhibitors of USP30 are provided. In some embodiments, methods of treating conditions involving mitochondrial defects are provided.

Abstract: The present invention relates to a feeding bottle device (100) comprising at least one air vent valve (140) for allowing the passage of air from outside the feeding bottle device (100) to within a container volume (125) when the feeding bottle device (100) is assembled, a confined volume forming component (150) for defining a confined volume (155) within a container volume (125) of a container component (120) of the feeding bottle device (100), wherein the confined volume (155) is configured to provide a controlled opening (165) for air entering through the air vent valve (140) into the container volume (125), and an optional duct forming component (170) for forming a guidance duct (175) from the at least one air vent valve (140) to the confined volume (155). The feeding bottle device (100) reduces the risk of colic-like symptoms for an infant.

Abstract: The invention relates to a telecommunications system comprising at least a plurality of SA-cells. The invention provides a method for a terminal to facilitate establishment of a data connection between the terminal and at least one of the SA-cells. The method includes steps of, while the terminal is in an idle mode, the terminal transmitting an information request message (IRM) for the plurality of SA-cells and receiving, from each SA-cell of one or more SA-cells of the plurality of SA-cells, a message comprising at least information indicative of a strength with which the each SA-cell received the IRM. The method further includes the step of, at least partially based on the messages received from the one or more SA-cells, the terminal selecting an SA-cell of the plurality of SA-cells for establishing the data connection between the terminal and the selected SA-cell.

Abstract: Method for determining a parameter which is indicative for whether a patient is delirious or not, or is at risk of becoming delirious or not, wherein the method comprises the steps of: —providing electroencephalography (EEG) data comprising recording signals from at least two electrodes located on different locations on the patient's scalp during a predetermined time period, for instance at least 10 seconds, wherein at least one of the signals is recorded from the frontal half on the scalp; —processing said EEG data for obtaining a deviation signal from the two recording signals from the electrodes; —analyzing said deviation signal in the frequency spectrum for establishing slowing of said deviation signal and defining the parameter as the degree of slowing of said deviation signal which in combination with the locations of the recordings on the patient's scalp is indicative whether said patient is delirious or not, or is at risk of becoming delirious or not.

Abstract: A process for aerobic treatment of wastewater is provided, which process comprises: (a) supplying a liquid influent comprising wastewater to a reactor containing granular biomass; (b) subjecting the reaction mixture to aerobic conditions comprising a concentration of dissolved oxygen from 0.1 mg/L to 4.0 mg/L, and a hydraulic retention time from 0.5 to 72 hours; (c) separating the reaction mixture into granular biomass and treated wastewater; and (d) recycling separated granular biomass to the reaction mixture. A bioreactor for the process is also disclosed, comprising a reaction vessel provided with an aeration means, a solids separation device with an inlet in the lower part of the reaction vessel having an outlet line for solids arranged to transport separated solids to a riser driven by airlift action and arranged to transport the solids to the upper part of the reaction chamber.

Abstract: An anaerobic purification device for purification of wastewater, the anaerobic purification device comprising: a reactor tank (10) configured to, when in operation, have a sludge blanket formed at the bottom part; a fluid inlet (12) for, in operation, introducing influent into the reactor tank, the fluid inlet located in the lower section of the reactor tank (10); at least one gas-collecting system (13); at least one gas-liquid separation device (30); at least one riser pipe (22) connected to the at least one gas-collecting system (13) and discharging into the gas-liquid separation device (30); a downer pipe (24) connected to the gas-liquid separation device (30) and discharging into the bottom of the reactor tank (10); and a fluid outlet (16) comprising means for, in operation, varying the height of the fluid level (19) in the reactor tank within a predetermined range, the fluid outlet arranged at the upper section of the reactor tank (10); wherein the fluid level control means comprises: a fluid valve

Abstract: The invention provides compounds of Formula 1: and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.

Abstract: The invention provides compounds of Formula 1: and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.

Abstract: The invention provides compounds of Formula 1: and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.

Abstract: A gas-liquid separation device (30) for an anaerobic purification device for purification of wastewater, the gas-liquid separation device comprising: a gas-liquid riser pipe (32); a separation pipe (34) attached to the gas-liquid riser pipe (32), the separation pipe defining an angle with the direction perpendicular to the gas-liquid riser pipe between ?45 degrees and +45 degrees, the separation pipe (34) configured to receive fluid from the gas-liquid riser pipe (32); at least one pipe gas outlet (35) located, when assembled with an anaerobic purification device, in a surface along the separation pipe (34) facing away from the ground, the at least one pipe gas outlet (35) configured to lead at least a portion of the gas in the separation pipe (34) outside the gas-liquid separation device; a hydraulic cyclone (36) attached to the separation pipe (34), the hydraulic cyclone configured to receive fluid from the separation pipe; at least one cyclone gas outlet (37) located in the upper side of the hydraulic c

Abstract: The invention relates to shaped catalyst bodies for the oxidation of SO2 to SO3, which comprise vanadium, at least one alkali metal and sulfate on a silicon dioxide support material, wherein the shaped body has the shape of a cylinder having 3 or 4 hollow-cylindrical convexities, obtainable by extrusion of a catalyst precursor composition comprising vanadium, at least one alkali metal and sulfate on a silicon dioxide support material through the opening of an extrusion tool, wherein the opening of the extrusion tool has a cross section formed by 3 or 4 partly overlapping rings whose midpoints lie essentially on a circular line having a diameter of y, wherein the rings are bounded by an outer line lying on a circle having an external diameter x1 and an inner line lying on a circle having an internal diameter x2.

Abstract: The invention provides compounds of Formula XXIII: wherein R1 is hydrogen, alkyl, acyl, or silyl, R2 is hydrogen, alkyl, benzyl, acyl, or ester, and R3 is hydrogen, alkyl, an aromatic group, azacyclic, carbocycle, aryl, cycloalkyl, heterocycloalkyl, heterocycle, heteroaryl, heteroalkyl, acyl, or ester, as well as derivatives and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.

Abstract: The present disclosure provides methods and compositions for enhanced editing of genomic DNA. For example, in some embodiments, a subject method is a method of editing genomic DNA of a eukaryotic cell and the method includes introducing into a eukaryotic cell a composition comprising: (a) a linearized non-homologous DNA composition and (b) a genome targeting composition (which includes a genome editing endonuclease, or a nucleic acid encoding the genome editing endonuclease). In some cases in which the genome editing endonuclease is a CRISPR/Cas endonuclease, the genome targeting composition can also include a corresponding CRISPR/Cas guide RNA.

Abstract: The invention provides compounds of Formula XXIII: wherein R1 is hydrogen, alkyl, acyl, or silyl, R2 is hydrogen, alkyl, benzyl, acyl, or ester, and R3 is hydrogen, alkyl, an aromatic group, azacyclic, carbocycle, aryl, cycloalkyl, heterocycloalkyl, heterocycle, heteroaryl, heteroalkyl, acyl, or ester, as well as derivatives and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.

Abstract: The invention provides compounds of Formula 1: and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.

Abstract: The invention provides compounds of Formula 1: and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.

Abstract: The invention provides compounds of Formula 1: and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.

Abstract: Inhibitors of USP30 and methods of using inhibitors of USP30 are provided. In some embodiments, methods of treating conditions involving mitochondrial defects are provided.